Literature DB >> 21177223

Analysing the external supply chain risk driver competitiveness: a risk mitigation framework and business continuity plan.

Mauricio F Blos1, Hui-Ming Wee, Joshua Yang.   

Abstract

Innovation challenges for handling supply chain risks have become one of the most important drivers in business competitiveness and differentiation. This study analyses competitiveness at the external supply chain level as a driver of risks and provides a framework for mitigating these risks. The mitigation framework, also called the supply chain continuity framework, provides insight into six stages of the business continuity planning (BCP) process life cycle (risk mitigation management, business impact analysis, supply continuity strategy development, supply continuity plan development, supply continuity plan testing and supply continuity plan maintenance), together with the operational constructs: customer service, inventory management, flexibility, time to market, ordering cycle time and quality. The purpose of the BCP process life cycle and operational constructs working together is to emphasise the way in which a supply chain can deal with disruption risks and, consequently, bring competitive advantage. Future research will consider the new risk scenarios and analyse the consequences to promote the improvement of supply chain resilience.

Entities:  

Mesh:

Year:  2010        PMID: 21177223

Source DB:  PubMed          Journal:  J Bus Contin Emer Plan        ISSN: 1749-9216


  2 in total

Review 1.  Business and continuity of operations: care of the critically ill and injured during pandemics and disasters: CHEST consensus statement.

Authors:  Pritish K Tosh; Henry Feldman; Michael D Christian; Asha V Devereaux; Niranjan Kissoon; Jeffrey R Dichter
Journal:  Chest       Date:  2014-10       Impact factor: 9.410

2.  Pharmaceutical supply chain risks: a systematic review.

Authors:  Mona Jaberidoost; Shekoufeh Nikfar; Akbar Abdollahiasl; Rassoul Dinarvand
Journal:  Daru       Date:  2013-12-19       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.